[1] Koshy AN, Gow PJ, Han HC,et al. Cardiovascular mortality following liver transplantation: predictors and temporal trends over 30 years. Eur Heart J Qual Care Clin Outcomes, 2020,6(4):243-253. [2] Chen YL, Zhao ZW, Li SM,et al. Value of red blood cell distribution width in prediction of diastolic dysfunction in cirrhotic cardiomyopathy. World J Gastroenterol, 2023,29(15):2322-2335. [3] Wiese S, Hove JD, Mo S,et al. Cardiac dysfunction in cirrhosis: a 2-yr longitudinal follow-up study using advanced cardiac imaging. Am J Physiol Gastrointest Liver Physiol, 2019,317(3):G253-G263. [4] Kapoor N, Mehta V, Singh B, et al. Prevalence of cirrhotic cardiomyopathy and its relationship with serum pro-brain natriuretic peptide, hepatorenal syndrome, spontaneous bacterial peritonitis, and mortality. Indian J Gastroenterol, 2020,39(5):481-486. [5] Zardi EM, Giorgi C, Dobrina A, et al. Analogies and differences between cirrhotic cardiomyopathy and hepatopulmonary syndrome. Med Res Rev, 2021,41(2):739-753. [6] Giannelli V, Roux O, Laouénan C,et al. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol, 2020,72(3):463-471. [7] 中华医学会肝病学分会. 肝硬化诊治指南.实用肝脏病杂志,2019,22(6):770-792. [8] European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol, 2018,69(2):406-460. [9] Marella HK, Kamal F, Peravali R,et al. Left ventricular diastolic dysfunction in liver transplantation: a stronger association with non-alcoholic steatohepatitis. Clin Exp Hepatol, 2020,6(2):158-162. [10] Sakr AE, Fraser GE, Doctorian TP,et al. Predictors of systolic heart failure and mortality following orthotopic liver transplantation: a single-center cohort. Transplant Proc, 2019,51(6):1950-1955. [11] Alvarado-Tapias E, Ardevol A, Garcia-Guix M,et al. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol, 2020,73(4):829-841. [12] Bi S, Jiang Y, Zhao W, et al. The predictive value of revised diastolic dysfunction in outcomes of liver transplantation: A propensity score matching analysis. Front Surg, 2023,9(1):1072908. [13] Razpotnik M, Bota S, Wimmer P,et al. The prevalence of cirrhotic cardiomyopathy according to different diagnostic criteria. Liver Int, 2021,41(5):1058-1069. [14] 刘玲玉,王韦,汤佳美. 超声三维斑点追踪技术早期诊断失代偿期肝硬化患者心肌损害应用价值分析. 实用肝脏病杂志,2023,26(3):400-403. [15] Sharma S, Karamchandani K, Wilson R,et al. Acute heart failure after orthotopic liver transplantation: a case series from one center. BMC Anesthesiol, 2018,18(1):102. [16] Rimba RC, Rimbas M, Chitroceanu AM, et al. Cirrhotic cardiomyopathy in the era of liver transplantation: time for precise stepwise evaluation. J Gastrointestin Liver Dis, 2020,29(4):665-675. [17] Li S, Hao X, Liu S, et al. Prolonged QTc interval predicts long-term mortality in cirrhosis: a propensity score matching analysis. Scand J Gastroenterol, 2021,56(5):570-577. [18] Kim KS, Kwon HM, Jung KW,et al. Markedly prolonged QTc interval in end-stage liver disease and risk of 30-day cardiovascular event after liver transplant. J Gastroenterol Hepatol, 2021,36(3):758-766. [19] Anikhindi SA, Ranjan P, Kumar M,et al. A prospective study of prevalence and predictors of cirrhotic cardiomyopathy and its role in development of hepatorenal syndrome. J Clin Exp Hepatol, 2022,12(3):853-860. [20] Abdul Aziz KA, Draman N, Wan Isa WYH,et al. Diastolic dysfunction in patients with liver cirrhosis: A short-term, observational study at a Malaysian hospital. Med J Malaysia, 2020,75(4):396-399. [21] Spann A, Coe C, Ajayi T,et al. Cirrhotic cardiomyopathy: Appraisal of the original and revised criteria in predicting posttransplant cardiac outcomes. Liver Transpl, 2022,28(8):1321-1331. |